Literature DB >> 6748093

Increased myocardial adenosine release in heart failure.

W H Newman, S J Grossman, M B Frankis, J G Webb.   

Abstract

Volume overload congestive heart failure in dogs is associated with a reduced myocardial inotropic responsiveness to the exogenous administration of beta-adrenergic agonists [10, 11]. This same blunted inotropic responsiveness to beta-agonists has now been identified in the failing human myocardium [2]. Volume overload congestive heart failure in dogs is also associated with a reduced resting coronary vascular resistance [7, 12] suggesting the possibility of increased myocardial production of a metabolic vasodilator in the failing heart. Adenosine is a metabolic coronary vasodilator [1] and also has recently been shown to antagonize the inotropic action of beta-adrenergic agonists through a mechanism involving action on the sarcolemmal adenylate cyclase system [4, 13]. Given the findings of blunted inotropic responsiveness of the failing myocardium to beta-adrenergic agonists and reduced coronary vascular resistance in heart failure, we hypothesized that heart failure was associated with elevated myocardial production of adenosine. Accordingly we measured myocardial adenosine release in normal dogs and dogs with volume overload heart failure. Basal levels of myocardial adenosine release were found to be elevated three-fold above normal in dogs with heart failure. It is possible that elevated adenosine release in the failing myocardium contributes both to abnormalities of coronary blood flow and to the blunted inotropic responsiveness of the failing heart to catecholamines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6748093     DOI: 10.1016/s0022-2828(84)80645-8

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

Review 1.  Adenosine receptors and the kidney.

Authors:  Volker Vallon; Hartmut Osswald
Journal:  Handb Exp Pharmacol       Date:  2009

Review 2.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 3.  Selective updates on mechanisms of action of positive inotropic agents.

Authors:  G Grupp
Journal:  Mol Cell Biochem       Date:  1987-08       Impact factor: 3.396

4.  Angiotensin AT1 receptor blockade abolishes the reflex sympatho-excitatory response to adenosine.

Authors:  G A Rongen; S C Brooks; S i Ando; B L Abramson; J S Floras
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.

Authors:  M Ungerer; M Böhm; R H Schwinger; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

6.  Inotropic response to DPI 201-106 in the failing human heart.

Authors:  M Böhm; F Diet; B Kemkes; M Wankerl; E Erdmann
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  Endogenous adenosine improves work rate to oxygen consumption ratio in catecholamine stimulated isovolumic rat heart.

Authors:  J Headrick; R J Willis
Journal:  Pflugers Arch       Date:  1989-02       Impact factor: 3.657

Review 8.  [Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs].

Authors:  M Böhm; R H Schwinger; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-09-14

9.  The anti-adrenergic effect of adenosine and its blockade by pertussis toxin: a comparative study in myocytes isolated from guinea-pig, rat and failing human hearts.

Authors:  L A Brown; S M Humphrey; S E Harding
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

Review 10.  Adenosine and kidney function: potential implications in patients with heart failure.

Authors:  Volker Vallon; Cindy Miracle; Scott Thomson
Journal:  Eur J Heart Fail       Date:  2008-02-01       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.